Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.1MCash on Hand
0.9mo Cash Runway
Follow RADX by emailGet an email when RADX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RADX, unsubscribe in one click. Privacy
📣 What RADX Says Is Next
by year-end · ““We believe the upcoming discussion will provide important alignment on the clinical and regulatory pathway forward, enabling us to finalize plans for a registrational study and remain on track to be Phase 3-ready by year-end.”
Company press release, Aug 17, 2026 · SEC filing
2H 2026 · “RAD 301 has previously received Orphan Drug Designation (ODD) from the FDA and data from the Phase 1 trial is supportive of the Company’s decision to move to a Phase 2 imaging trial in patients with loco-regional pancreatic cancer. · Enrollment in the Phase 1 imaging trial in metastatic pancreatic cancer continues, having dosed 8 patients out of 9, with last patient expected to be dosed in 2H 2026.”
Company press release, Jul 31, 2026 · SEC filing
Q4 2026 · “The Company anticipates the initiation of a Phase 3, multi-center, multi-country registrational study in Q4 2026.”
Company press release, Jul 31, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial Presented interim Phase 2b RAD101 data at SNO26 in suspected recurrent brain metastases: 93.5% patient-level concordance with MRI, 85.7% preliminary sensitivity among 16 evaluable participants, and no treatment-emergent serious adverse events in 32 dosed. Final analyses expected Q1 2027. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Leadership Filed a copy of an ASX notice reporting that directors Bruce Goodwin, Ian Turner and Riccardo Canevari sold shares on 5 November 2026 at $0.0035 and $0.0040 per share, following an ASX announcement dated 12 October 2026. Form 6-K · SEC filing · Press release
Nov 4, 2026 ·
Regulatory Radiopharm reached alignment with the FDA on a single pivotal Phase 3 imaging trial of RAD101 in about 280 patients with indeterminate brain metastases. Clinical supply will come from Siemens Healthineers, with dosing expected to begin in the first half of 2027. Form 6-K · SEC filing · Press release
Oct 30, 2026 ·
Clinical trial Radiopharm reported Q1 business updates including a successful End-of-Phase 2 FDA meeting for RAD101 ahead of a Phase 3 trial starting 1Q27, positive Phase 1 imaging data for RAD301, and completion of a A$12.5 million institutional offer plus a A$3 million Share Purchase Plan. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Shareholder vote Radiopharm Theranostics filed a notice of its annual general meeting on 25 November 2026, virtual only via Automic. Shareholders will vote on the remuneration report, the election of Mr Bruce Goodwin as director, issuing securities under the Omnibus Incentive Plan, and a 10% capacity under Listing Rule 7.1A. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Financing Radiopharm received $8,000,000 from Rockford Capital under a funding facility secured against its anticipated FY26 R&D tax incentive. Interest is charged at a commercial rate, and repayment is due by 26 October 2027 without penalty for early repayment. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Regulatory Radiopharm completed an End-of-Phase 2 meeting with the FDA on RAD101 for brain metastases imaging and expects official meeting minutes within about 30 days. The company is advancing Phase 3 readiness and exploring strategic partnering opportunities. Form 6-K · SEC filing · Press release
Oct 1, 2026 ·
Leadership Director Riccardo Canevari's unlisted options expired on 30 September 2026, reducing his options holdings from 187,301,188 to 163,301,188. His direct and indirect share holdings were unchanged. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 1 · Upcoming Trial · A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors Registry primary completion date, not a results date
Dec 2027 · Early Phase 1 · Recruiting · HEAT Trial (HER2 Antibody Therapy With Lutetium-177) Registry primary completion date, not a results date
Dec 2027 · Early Phase 1 · Recruiting · 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors Registry primary completion date, not a results date
Nov 2028 · Phase 1/2 · Recruiting · A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC Registry primary completion date, not a results date
Apr 2026 · Phase 2 · Active Trial · Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RADX holds $4.1M in cash and short-term investments and burns about $13.2M/quarter from operations,
an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:84 · High
Cash runway 1 months +40
ATM program on file since Jul 2026 +15
Shelf registration (F-3, Dec 2025) +10
Going-concern doubt in the latest 20-F +15These conditions, along with other matters as set forth in Note 20(a)(iii), raise substantial doubt about the Group’s ability to continue as a going concern.20-F, Sep 2026
Share count +50% in a year +14
Raised after last reported balance sheet (Jul 2026) -10
Share count 3,544,216,160 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RADX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RADX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.